Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 1.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,680 shares of the company’s stock after buying an additional 4,350 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Teva Pharmaceutical Industries were worth $2,125,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. First National Bank of South Miami acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $31,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in Teva Pharmaceutical Industries by 329.9% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 4,020 shares of the company’s stock worth $39,000 after acquiring an additional 3,085 shares in the last quarter. Advisory Alpha LLC grew its stake in Teva Pharmaceutical Industries by 161.8% in the first quarter. Advisory Alpha LLC now owns 4,045 shares of the company’s stock valued at $41,000 after acquiring an additional 2,500 shares during the period. NEXT Financial Group Inc increased its holdings in shares of Teva Pharmaceutical Industries by 77.0% in the first quarter. NEXT Financial Group Inc now owns 6,824 shares of the company’s stock worth $61,000 after acquiring an additional 2,969 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its position in shares of Teva Pharmaceutical Industries by 2,322.9% during the first quarter. Cullen Frost Bankers Inc. now owns 8,989 shares of the company’s stock worth $81,000 after purchasing an additional 8,618 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Shares of TEVA opened at $12.19 on Tuesday. The stock has a 50 day moving average of $12.17 and a 200 day moving average of $10.65. The company has a market capitalization of $13.31 billion, a price-to-earnings ratio of 4.94, a PEG ratio of 0.86 and a beta of 1.64. Teva Pharmaceutical Industries Ltd has a 12 month low of $6.07 and a 12 month high of $13.76. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.68.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, May 7th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.17. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.4 earnings per share for the current year.

A number of equities analysts recently weighed in on the stock. Citigroup started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, April 24th. They issued a “neutral” rating for the company. Piper Sandler dropped their target price on Teva Pharmaceutical Industries from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. ValuEngine downgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a report on Monday, May 11th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Zacks Investment Research lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and set a $13.00 price target on the stock. in a research report on Thursday, June 11th. Five research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $11.58.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.